JPH0645639B2 - ペプチド誘導体 - Google Patents
ペプチド誘導体Info
- Publication number
- JPH0645639B2 JPH0645639B2 JP62257047A JP25704787A JPH0645639B2 JP H0645639 B2 JPH0645639 B2 JP H0645639B2 JP 62257047 A JP62257047 A JP 62257047A JP 25704787 A JP25704787 A JP 25704787A JP H0645639 B2 JPH0645639 B2 JP H0645639B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- peptide
- compound
- resin
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title description 66
- 150000001875 compounds Chemical class 0.000 description 91
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 229920005989 resin Polymers 0.000 description 30
- 239000011347 resin Substances 0.000 description 30
- 239000000203 mixture Substances 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 102000018997 Growth Hormone Human genes 0.000 description 18
- 108010051696 Growth Hormone Proteins 0.000 description 18
- 239000000122 growth hormone Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 125000006239 protecting group Chemical group 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- -1 polyethylene Polymers 0.000 description 10
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 9
- 108010016076 Octreotide Proteins 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 229960002700 octreotide Drugs 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004036 acetal group Chemical group 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 5
- 125000003158 alcohol group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- MUVQIIBPDFTEKM-QWWZWVQMSA-N (2r,3r)-2-aminobutane-1,3-diol Chemical group C[C@@H](O)[C@H](N)CO MUVQIIBPDFTEKM-QWWZWVQMSA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 4
- 206010000599 Acromegaly Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229920003002 synthetic resin Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 238000006359 acetalization reaction Methods 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 230000003294 somatostatinlike Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HBDJFVFTHLOSDW-DNDLZOGFSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;hydrate Chemical compound O.O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HBDJFVFTHLOSDW-DNDLZOGFSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- OYNIIKHNXNPSAG-UHFFFAOYSA-N 2-(4-formylphenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(C=O)C=C1 OYNIIKHNXNPSAG-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 238000011672 OFA rat Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000005521 carbonamide group Chemical group 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- LLHRMWHYJGLIEV-UHFFFAOYSA-N desoxy Chemical group COC1=CC(CCN)=CC(OC)=C1C LLHRMWHYJGLIEV-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VMVNZNXAVJHNDJ-UHFFFAOYSA-N methyl 2,2,2-trifluoroacetate Chemical compound COC(=O)C(F)(F)F VMVNZNXAVJHNDJ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3634825 | 1986-10-13 | ||
| DE3634825.2 | 1986-10-13 | ||
| DE3634797.3 | 1986-10-13 | ||
| DE3634797 | 1986-10-13 | ||
| DE3634826 | 1986-10-13 | ||
| DE3634826.0 | 1986-10-13 | ||
| DE3712626 | 1987-04-14 | ||
| DE3712626.1 | 1987-04-14 | ||
| CH3634826.0 | 1987-08-17 | ||
| CH3634797.3 | 1987-08-17 | ||
| CH3153/87-6 | 1987-08-17 | ||
| CH315387 | 1987-08-17 | ||
| CH3712626.1 | 1987-08-17 | ||
| CH3634825.2 | 1987-08-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2147161A Division JP2744910B2 (ja) | 1986-10-13 | 1990-06-04 | ペプチド誘導体類 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63101399A JPS63101399A (ja) | 1988-05-06 |
| JPH0645639B2 true JPH0645639B2 (ja) | 1994-06-15 |
Family
ID=27509117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62257047A Expired - Lifetime JPH0645639B2 (ja) | 1986-10-13 | 1987-10-12 | ペプチド誘導体 |
| JP2147161A Expired - Lifetime JP2744910B2 (ja) | 1986-10-13 | 1990-06-04 | ペプチド誘導体類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2147161A Expired - Lifetime JP2744910B2 (ja) | 1986-10-13 | 1990-06-04 | ペプチド誘導体類 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5656721A (OSRAM) |
| JP (2) | JPH0645639B2 (OSRAM) |
| KR (1) | KR960016861B1 (OSRAM) |
| AU (2) | AU617986B2 (OSRAM) |
| BE (1) | BE1003752A4 (OSRAM) |
| CA (1) | CA1340985C (OSRAM) |
| CH (2) | CH680512A5 (OSRAM) |
| DE (1) | DE3790635T1 (OSRAM) |
| DK (1) | DK174337B1 (OSRAM) |
| ES (1) | ES2007418A6 (OSRAM) |
| FI (1) | FI874495A7 (OSRAM) |
| FR (1) | FR2609991A1 (OSRAM) |
| GB (2) | GB2199829B (OSRAM) |
| GR (1) | GR871567B (OSRAM) |
| HU (3) | HU906340D0 (OSRAM) |
| IE (1) | IE912442A1 (OSRAM) |
| LU (1) | LU87014A1 (OSRAM) |
| NL (1) | NL194729C (OSRAM) |
| NZ (1) | NZ222133A (OSRAM) |
| PL (1) | PL157156B1 (OSRAM) |
| PT (1) | PT85904B (OSRAM) |
| SE (2) | SE8703938L (OSRAM) |
| WO (1) | WO1988002756A2 (OSRAM) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU906340D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| DE3822557C2 (de) * | 1987-07-10 | 1998-07-02 | Ciba Geigy Ag | Arzneimittel, enthaltend Somatostatine |
| WO1989007109A1 (en) * | 1988-02-01 | 1989-08-10 | The Upjohn Company | Renin inhibiting peptides with polar end groups |
| DK163689A (da) * | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
| DE3910667A1 (de) * | 1988-04-11 | 1989-10-19 | Sandoz Ag | Peptidderivate |
| GB8813339D0 (en) * | 1988-06-06 | 1988-07-13 | Sandoz Ltd | Improvements in/relating to organic compounds |
| BE1003762A3 (fr) * | 1988-11-11 | 1992-06-09 | Sandoz Sa | Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives. |
| MY106120A (en) * | 1988-12-05 | 1995-03-31 | Novartis Ag | Peptide derivatives. |
| US5776894A (en) * | 1988-12-05 | 1998-07-07 | Novartis Ag | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors |
| US5753627A (en) * | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
| IT1229514B (it) * | 1989-01-30 | 1991-09-03 | Farmhispania S A A Montme | Glicoconiugati anfifilici sintetici per impiego neurologico. |
| DK111489D0 (da) * | 1989-03-08 | 1989-03-08 | Novo Nordisk As | Peptider |
| DE4206858A1 (de) * | 1992-03-05 | 1993-09-09 | Behringwerke Ag | Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel |
| IT1260156B (it) * | 1992-08-03 | 1996-03-28 | Fidia Spa | Derivati dell'acido neuraminico |
| TW263437B (OSRAM) * | 1992-09-24 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| US5710244A (en) * | 1992-12-31 | 1998-01-20 | Labroo; Virender M. | Derivatized calcitonins |
| US5508387A (en) * | 1993-08-04 | 1996-04-16 | Glycomed Incorporated | Selectin binding glycopeptides |
| DE69435105D1 (de) * | 1993-08-09 | 2008-08-07 | Sod Conseils Rech Applic | Derivate therapeutischer Peptide |
| US5556939A (en) * | 1994-10-13 | 1996-09-17 | Merck Frosst Canada, Inc. | TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications |
| US5632969A (en) * | 1994-10-13 | 1997-05-27 | Merck & Co., Inc. | N3 S2 chelating ligands optionally radiolabelled with Tc or Re, useful for diagnostic or therapeutic applications |
| JP3896430B2 (ja) * | 1996-07-15 | 2007-03-22 | アークレイ株式会社 | 糖化アミノ化合物の製造方法 |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| EP0981364B1 (en) | 1997-05-13 | 2006-03-01 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Method and compositions for treating hyperlipidemia |
| EP0981363B1 (en) | 1997-05-13 | 2003-07-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Somatostatin agonists for decreasing body weight |
| US6004928A (en) * | 1997-05-13 | 1999-12-21 | Biomeasure, Incorporated | Method of treating hyperlipidemia |
| AU766653B2 (en) * | 1998-02-13 | 2003-10-23 | Amylin Pharmaceuticals, Inc. | Novel mixed amylin activity compounds |
| US5968903A (en) * | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
| US20050037490A1 (en) * | 1999-10-29 | 2005-02-17 | Lawrence Rosenberg | Medium for preparing dedifferentiated cells |
| DE60231801D1 (de) * | 2001-04-23 | 2009-05-14 | Mallinckrodt Inc | Tc und re markierte radioaktive glycosylierte octreotid-derivate |
| CN1514843A (zh) | 2001-06-08 | 2004-07-21 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 生长激素释放抑制因子-多巴胺嵌合类似物 |
| EP1480998B1 (en) * | 2002-02-27 | 2006-11-22 | Ferring BV | Intermediates and methods for making heptapeptide oxytocin analogues |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2007025286A2 (en) * | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| PL1787658T3 (pl) | 2005-11-10 | 2012-08-31 | Italfarmaco Spa | Formulacje o przedłużonym uwalnianiu analogów somatostatyny będących inhibitorami hormonu wzrostu |
| WO2008011168A2 (en) * | 2006-07-21 | 2008-01-24 | Amgen Inc. | Glycosylated peptide antagonists of the bradykinin b1 receptor |
| CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| KR101623985B1 (ko) | 2007-03-28 | 2016-05-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| CA2700587A1 (en) | 2007-09-25 | 2009-04-02 | Glycom A/S | Glycoproteins and glycosylated cells and a method for the preparation of the same |
| CA2713394C (en) * | 2007-11-09 | 2016-01-19 | Charles Yates | Anti-inflammatory quinic acid derivatives for oral administration |
| EP2719392B1 (en) | 2008-06-12 | 2019-07-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatment of acromegaly |
| CN107446053A (zh) | 2008-06-12 | 2017-12-08 | 益普生生物创新有限公司 | 癌症的抑制 |
| WO2010089757A2 (en) * | 2008-11-07 | 2010-08-12 | Usv Limited | An improved process for synthesis of cyclic octapeptide |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| SG10201601327RA (en) | 2011-09-04 | 2016-03-30 | Glytech Inc | Glycosylated polypeptide and drug composition containing said polypeptide |
| AU2012302636B2 (en) | 2011-09-04 | 2016-09-15 | Glytech, Inc. | Glycosylated polypeptide and drug composition containing said polypeptide |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| AU2014280847B2 (en) | 2013-06-13 | 2019-07-04 | Antisense Therapeutics Ltd | Combination therapy |
| CN106999541A (zh) | 2014-09-24 | 2017-08-01 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| WO2016112205A1 (en) | 2015-01-07 | 2016-07-14 | Trigemina, Inc. | Magnesium-containing oxytocin formulations and methods of use |
| MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| EP4541348A3 (en) | 2016-04-12 | 2025-06-04 | Tonix Pharma Limited | Magnesium-containing oxytocin formulations and methods of use |
| EP3713545A1 (en) | 2017-11-22 | 2020-09-30 | Dauntless 1, Inc. | Therapeutic compound formulations |
| WO2019104214A1 (en) | 2017-11-22 | 2019-05-31 | Dauntless 2, Inc. | Membrane emulsification device for microsphere creation |
| WO2020005842A1 (en) | 2018-06-25 | 2020-01-02 | Dauntless 2, Inc. | Membrane emulsification device with impeller for microsphere creation |
| WO2020212477A1 (en) | 2019-04-16 | 2020-10-22 | Bachem Holding Ag | Manufacture of disulfide bonded peptides |
| EP4232464A4 (en) * | 2020-10-22 | 2025-02-12 | The Trustees of Indiana University | MOLECULAR DESIGNS OF GLUCOSE-RESPONSIVE AND GLUCOSE-CLAVABLE INSULIN ANALOGUES |
| WO2025229200A1 (en) | 2024-05-03 | 2025-11-06 | Bachem Holding Ag | Manufacture of disulfide bonded peptides |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254023A (en) * | 1979-10-16 | 1981-03-03 | Pennwalt Corporation | Synthesis of peptide alcohols by the solid phase method |
| US4280953A (en) * | 1979-11-08 | 1981-07-28 | The Salk Institute For Biological Studies | Glycosylated analogs of somatostatin |
| ATE2512T1 (de) * | 1979-11-27 | 1983-03-15 | Sandoz Ag | Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung. |
| FR2522967B1 (fr) * | 1982-03-15 | 1986-03-07 | Anvar | Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant |
| US4444683A (en) * | 1982-11-17 | 1984-04-24 | University Of Utah | Glycosylated insulin derivatives |
| US4483792A (en) * | 1982-11-17 | 1984-11-20 | Kim Wan S | Glycosylated insulin derivatives |
| FR2546163B1 (fr) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
| FR2548673B1 (fr) * | 1983-07-05 | 1985-10-04 | Essilor Int | Polymeres supports de produits actifs relargables et leur procede de preparation |
| LU85269A1 (fr) * | 1984-03-26 | 1985-10-14 | Techland S A | Composes nouveaux de somatostatine,procede pour leur synthese,preparation a usage veterinaire contenant lesdits composes et procede pour le traitement d'animaux |
| US4564998A (en) * | 1984-10-19 | 1986-01-21 | Westinghouse Electric Corp. | Coil winding methods and apparatus |
| DE3439610A1 (de) * | 1984-10-30 | 1986-04-30 | Boehringer Mannheim Gmbh, 6800 Mannheim | Immunogene, verfahren zu deren herstellung sowie damit gewonnene antikoerper gegen glykosiliertes haemoglobin |
| FI860708A7 (fi) * | 1985-02-20 | 1986-08-21 | Ciba Geigy Ag | Acylerade hexosderivat och foerfarande foer deras framstaellning. |
| JPS61264260A (ja) * | 1985-05-17 | 1986-11-22 | Rikagaku Kenkyusho | アルデヒド化多孔性高分子材料によるタンパク質の除去方法 |
| CA1337041C (en) * | 1985-10-09 | 1995-09-19 | Brett Alan Evans | Granular detergent compositions having improved solubility |
| SE8506094D0 (sv) * | 1985-12-20 | 1985-12-20 | Astra Laekemedel Ab | New antibacterial agents and intermediates therefor |
| JPS63165411A (ja) * | 1986-09-11 | 1988-07-08 | Tokyo Organ Chem Ind Ltd | アルデヒド基を有する架橋共重合体の製法 |
| JPS63165410A (ja) * | 1986-09-11 | 1988-07-08 | Tokyo Organ Chem Ind Ltd | アルデヒド基を有する架橋共重合体の製造方法 |
| HU906340D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| US4859736A (en) * | 1987-03-30 | 1989-08-22 | Ciba-Geigy Corporation | Synthetic polystyrene resin and its use in solid phase peptide synthesis |
| CH679045A5 (OSRAM) * | 1987-06-29 | 1991-12-13 | Sandoz Ag |
-
1987
- 1987-10-01 HU HU906340A patent/HU906340D0/hu unknown
- 1987-10-01 HU HU874432A patent/HU206890B/hu not_active IP Right Cessation
- 1987-10-01 HU HU906341A patent/HU906341D0/hu unknown
- 1987-10-01 NL NL8702345A patent/NL194729C/nl not_active IP Right Cessation
- 1987-10-07 LU LU87014A patent/LU87014A1/fr unknown
- 1987-10-07 FR FR8713949A patent/FR2609991A1/fr active Granted
- 1987-10-09 GB GB8723737A patent/GB2199829B/en not_active Expired - Lifetime
- 1987-10-09 BE BE8701187A patent/BE1003752A4/fr not_active IP Right Cessation
- 1987-10-12 KR KR1019870011265A patent/KR960016861B1/ko not_active Expired - Lifetime
- 1987-10-12 SE SE8703938A patent/SE8703938L/ not_active Application Discontinuation
- 1987-10-12 FI FI874495A patent/FI874495A7/fi not_active Application Discontinuation
- 1987-10-12 DK DK198705327A patent/DK174337B1/da not_active IP Right Cessation
- 1987-10-12 PT PT85904A patent/PT85904B/pt unknown
- 1987-10-12 CH CH3804/90A patent/CH680512A5/de not_active IP Right Cessation
- 1987-10-12 NZ NZ222133A patent/NZ222133A/xx unknown
- 1987-10-12 JP JP62257047A patent/JPH0645639B2/ja not_active Expired - Lifetime
- 1987-10-12 DE DE19873790635 patent/DE3790635T1/de active Pending
- 1987-10-12 GR GR871567A patent/GR871567B/el unknown
- 1987-10-12 WO PCT/EP1987/000593 patent/WO1988002756A2/en not_active Ceased
- 1987-10-12 AU AU79564/87A patent/AU617986B2/en not_active Ceased
- 1987-10-12 PL PL1987268173A patent/PL157156B1/pl unknown
- 1987-10-12 CH CH1353/89A patent/CH682632A5/de not_active IP Right Cessation
- 1987-10-13 ES ES8702913A patent/ES2007418A6/es not_active Expired
- 1987-10-13 CA CA000549140A patent/CA1340985C/en not_active Expired - Lifetime
-
1988
- 1988-01-12 GB GB8800537A patent/GB2199831B/en not_active Expired - Lifetime
-
1990
- 1990-06-04 JP JP2147161A patent/JP2744910B2/ja not_active Expired - Lifetime
-
1991
- 1991-07-03 AU AU80150/91A patent/AU634664B2/en not_active Expired
- 1991-07-12 IE IE244291A patent/IE912442A1/en unknown
-
1993
- 1993-04-07 SE SE9301172A patent/SE518630C2/sv unknown
-
1994
- 1994-07-07 US US08/272,704 patent/US5656721A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0645639B2 (ja) | ペプチド誘導体 | |
| DE69615838T2 (de) | Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität | |
| US4703034A (en) | Novel cyclic tetrapeptide | |
| EP0485458B1 (en) | Thioacylating reagents and intermediates, thiopeptides, and methods for preparing and using same | |
| US4405607A (en) | Novel pentapeptides, processes for their production, pharmaceutical compositions comprising said pentapeptides and their use | |
| FR2522655A1 (fr) | Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant | |
| US4837305A (en) | Derivatives of β-adrenergic antagonists | |
| US7365055B2 (en) | Derivatives of morphine-6-glucuronide, pharmaceutical compositions containing them, their preparation method and their uses | |
| WO1995024421A1 (en) | Peptide derivative | |
| FR2619566A1 (fr) | Procede de preparation d'un peptide-alcool | |
| EP0117089B1 (en) | Beta-adrenergic antagonist compounds and derivatives of beta-adrenergic antagonists | |
| AU651557C (en) | Thioacylating reagents and intermediates, thiopeptides, and methods for preparing and using same | |
| JP3554399B2 (ja) | ペプチド誘導体 | |
| EP0001335B1 (en) | A peptide, processes for its preparation and compositions containing the same | |
| GB2233652A (en) | Synthesis of peptide alcohols | |
| US4356119A (en) | Therapeutically active polypeptides or acid addition salts and a process for producing such compounds | |
| FR2629824A1 (fr) | Nouveaux peptides de la somatostatine, leur preparation et leur utilisation comme medicaments | |
| CH677233A5 (en) | New sugar derivs. of biologically active peptide(s) | |
| GB2227488A (en) | Modified somatostatin | |
| JPH06107681A (ja) | ペプチド誘導体 | |
| JPS6024120B2 (ja) | 新規なソマスタチン同族体 | |
| JPH10330399A (ja) | 神経伝達ポリペプチド |